Impact of Hemoglobin, Leucocyte and Thrombocyte Levels at Diagnosis on the Survival Outcomes of Chronic Myeloid Leukemia Patients

Background:Since the development of tyrosine kinase inhibitors (TKIs), the prognosis for chronic myeloid leukemia (CML) has significantly improved. Several predicted prognostic scores and indicators at diagnosis have been used to predict the prognosis of chronic phase chronic myeloid leukemia (CML-C...

Full description

Saved in:
Bibliographic Details
Main Authors: Taha Ulutan Kars, Atakan Tekinalp, Rafiye Ciftciler, Sinan Demircioğlu
Format: Article
Language:English
Published: Selcuk University Press 2024-02-01
Series:Genel Tıp Dergisi
Subjects:
Online Access:https://dergipark.org.tr/tr/download/article-file/3355952
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841562024144797696
author Taha Ulutan Kars
Atakan Tekinalp
Rafiye Ciftciler
Sinan Demircioğlu
author_facet Taha Ulutan Kars
Atakan Tekinalp
Rafiye Ciftciler
Sinan Demircioğlu
author_sort Taha Ulutan Kars
collection DOAJ
description Background:Since the development of tyrosine kinase inhibitors (TKIs), the prognosis for chronic myeloid leukemia (CML) has significantly improved. Several predicted prognostic scores and indicators at diagnosis have been used to predict the prognosis of chronic phase chronic myeloid leukemia (CML-CP) during the TKI period. When CML patients are first diagnosed, hemogram parameter aberrations are rather prevalent in clinical practice, although it is still unknown how those parameters affect the prognosis. This study aims to evaluate the hemogram parameters at diagnosis on the survival outcomes of CML-CP patients. Materials and Methods:One hundred thirty-seven patients who were diagnosed with CML-CP and received treatment were assessed between the years 2006 and 2020. Results:There were 65 (47.4%) males and 72 (52.6%) females with a median age of 50 (range: 18-78) years at diagnosis. Median hemoglobin level was 12.1 gr/dL (4.3-17.4), leucocyte count was 66.2 ×109 /L (7.5-520.2), and thrombocyte count was 362 ×109 /L (18-3.496) for all patients. The median progression-free survival (PFS) was 16.7 months 16.7 (2.0-106.4) and the median overall survival (OS) was 63.8 months (0.43-166.2) for all patients. Conclusion:This study is valuable in terms of predicting the prognosis of CML patients with hemoglobin, leukocyte, and platelet values at the time of diagnosis. While emphasizing the importance of platelet count at the time of diagnosis, similar to the previously defined risk scores, it showed that leukocyte and hemoglobin values at the time of diagnosis did not have a statistically significant effect on OS and PFS.
format Article
id doaj-art-aae294f029854d6cb7203c54f1157d52
institution Kabale University
issn 2602-3741
language English
publishDate 2024-02-01
publisher Selcuk University Press
record_format Article
series Genel Tıp Dergisi
spelling doaj-art-aae294f029854d6cb7203c54f1157d522025-01-03T01:13:46ZengSelcuk University PressGenel Tıp Dergisi2602-37412024-02-01341788210.54005/geneltip.1348459154Impact of Hemoglobin, Leucocyte and Thrombocyte Levels at Diagnosis on the Survival Outcomes of Chronic Myeloid Leukemia PatientsTaha Ulutan Kars0Atakan Tekinalp1Rafiye Ciftciler2Sinan Demircioğlu3NECMETTIN ERBAKAN UNIVERSITYNECMETTIN ERBAKAN UNIVERSITYSELÇUK ÜNİVERSİTESİ, TIP FAKÜLTESİNECMETTIN ERBAKAN UNIVERSITYBackground:Since the development of tyrosine kinase inhibitors (TKIs), the prognosis for chronic myeloid leukemia (CML) has significantly improved. Several predicted prognostic scores and indicators at diagnosis have been used to predict the prognosis of chronic phase chronic myeloid leukemia (CML-CP) during the TKI period. When CML patients are first diagnosed, hemogram parameter aberrations are rather prevalent in clinical practice, although it is still unknown how those parameters affect the prognosis. This study aims to evaluate the hemogram parameters at diagnosis on the survival outcomes of CML-CP patients. Materials and Methods:One hundred thirty-seven patients who were diagnosed with CML-CP and received treatment were assessed between the years 2006 and 2020. Results:There were 65 (47.4%) males and 72 (52.6%) females with a median age of 50 (range: 18-78) years at diagnosis. Median hemoglobin level was 12.1 gr/dL (4.3-17.4), leucocyte count was 66.2 ×109 /L (7.5-520.2), and thrombocyte count was 362 ×109 /L (18-3.496) for all patients. The median progression-free survival (PFS) was 16.7 months 16.7 (2.0-106.4) and the median overall survival (OS) was 63.8 months (0.43-166.2) for all patients. Conclusion:This study is valuable in terms of predicting the prognosis of CML patients with hemoglobin, leukocyte, and platelet values at the time of diagnosis. While emphasizing the importance of platelet count at the time of diagnosis, similar to the previously defined risk scores, it showed that leukocyte and hemoglobin values at the time of diagnosis did not have a statistically significant effect on OS and PFS.https://dergipark.org.tr/tr/download/article-file/3355952chronic myeloid leukemiahemoglobinleucocytethrombocyterisk scorechronic myeloid leukemiahemoglobinleucocytethrombocyterisk score
spellingShingle Taha Ulutan Kars
Atakan Tekinalp
Rafiye Ciftciler
Sinan Demircioğlu
Impact of Hemoglobin, Leucocyte and Thrombocyte Levels at Diagnosis on the Survival Outcomes of Chronic Myeloid Leukemia Patients
Genel Tıp Dergisi
chronic myeloid leukemia
hemoglobin
leucocyte
thrombocyte
risk score
chronic myeloid leukemia
hemoglobin
leucocyte
thrombocyte
risk score
title Impact of Hemoglobin, Leucocyte and Thrombocyte Levels at Diagnosis on the Survival Outcomes of Chronic Myeloid Leukemia Patients
title_full Impact of Hemoglobin, Leucocyte and Thrombocyte Levels at Diagnosis on the Survival Outcomes of Chronic Myeloid Leukemia Patients
title_fullStr Impact of Hemoglobin, Leucocyte and Thrombocyte Levels at Diagnosis on the Survival Outcomes of Chronic Myeloid Leukemia Patients
title_full_unstemmed Impact of Hemoglobin, Leucocyte and Thrombocyte Levels at Diagnosis on the Survival Outcomes of Chronic Myeloid Leukemia Patients
title_short Impact of Hemoglobin, Leucocyte and Thrombocyte Levels at Diagnosis on the Survival Outcomes of Chronic Myeloid Leukemia Patients
title_sort impact of hemoglobin leucocyte and thrombocyte levels at diagnosis on the survival outcomes of chronic myeloid leukemia patients
topic chronic myeloid leukemia
hemoglobin
leucocyte
thrombocyte
risk score
chronic myeloid leukemia
hemoglobin
leucocyte
thrombocyte
risk score
url https://dergipark.org.tr/tr/download/article-file/3355952
work_keys_str_mv AT tahaulutankars impactofhemoglobinleucocyteandthrombocytelevelsatdiagnosisonthesurvivaloutcomesofchronicmyeloidleukemiapatients
AT atakantekinalp impactofhemoglobinleucocyteandthrombocytelevelsatdiagnosisonthesurvivaloutcomesofchronicmyeloidleukemiapatients
AT rafiyeciftciler impactofhemoglobinleucocyteandthrombocytelevelsatdiagnosisonthesurvivaloutcomesofchronicmyeloidleukemiapatients
AT sinandemircioglu impactofhemoglobinleucocyteandthrombocytelevelsatdiagnosisonthesurvivaloutcomesofchronicmyeloidleukemiapatients